Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study

[1] Ito Y(2014)Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data Cancer Sci 105 1480-1486

[2] Miyashiro I(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825

[3] Ito H(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703

[4] Hosono S(2017)A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer Oncotarget 8 111346-111355

[5] Chihara D(2013)Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study J Clin Oncol 31 1640-1648

[6] Nakata-Yamada K(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 25 1960-1966

[7] Nakayama M(2020)Real-world data of the association between quality of life using the EuroQol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy Support Care Cancer 28 5943-5952

[8] Matsuzaka M(2015)The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients PLoS One 10 e0124169-3572

[9] Hattori M(2019)Frequency of low-grade adverse events and quality of life during chemotherapy determine patients’ judgement about treatment in advanced-stage thoracic cancer Support Care Cancer 27 3563-2556

[10] Sugiyama H(2018)Metastatic pancreatic Cancer: ASCO clinical practice guideline update J Clin Oncol 36 2545-654

[1] Ito Y(2014)Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data Cancer Sci 105 1480-1486

[2] Miyashiro I(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825

[3] Ito H(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703

[4] Hosono S(2017)A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer Oncotarget 8 111346-111355

[5] Chihara D(2013)Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study J Clin Oncol 31 1640-1648

[6] Nakata-Yamada K(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 25 1960-1966

[7] Nakayama M(2020)Real-world data of the association between quality of life using the EuroQol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy Support Care Cancer 28 5943-5952

[8] Matsuzaka M(2015)The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients PLoS One 10 e0124169-3572

[9] Hattori M(2019)Frequency of low-grade adverse events and quality of life during chemotherapy determine patients’ judgement about treatment in advanced-stage thoracic cancer Support Care Cancer 27 3563-2556

[10] Sugiyama H(2018)Metastatic pancreatic Cancer: ASCO clinical practice guideline update J Clin Oncol 36 2545-654